{"gene":"PIM3","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":2006,"finding":"PIM3 phosphorylates the pro-apoptotic protein BAD at Ser112 (but not Ser136) to inactivate it and prevent apoptosis in human pancreatic cancer cells; knockdown of PIM3 reduced BAD phosphorylation at Ser112 and Bcl-XL expression, promoting apoptosis.","method":"shRNA knockdown, Western blot for phospho-BAD (Ser112/Ser136), sub-G1 cell cycle analysis, phosphatidylserine externalization assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — replicated across multiple cancer types (pancreas, colon, liver) with orthogonal methods; foundational study with 156 citations","pmids":["16818649"],"is_preprint":false},{"year":2007,"finding":"PIM3 phosphorylates BAD at Ser112 in human colon cancer cells, and PIM3 co-localizes with phospho-Ser112-BAD in clinical colon cancer tissues, inactivating BAD to prevent apoptosis.","method":"shRNA knockdown, Western blot, immunohistochemistry co-localization","journal":"Cancer science","confidence":"High","confidence_rationale":"Tier 2 — independent replication of BAD-Ser112 phosphorylation mechanism in a second cancer type","pmids":["17270021"],"is_preprint":false},{"year":2005,"finding":"PIM3 promotes hepatoma cell proliferation and prevents apoptosis; siRNA-mediated ablation of PIM3 attenuates proliferation and enhances apoptosis in human hepatoma cell lines.","method":"RNA interference, cell proliferation assay, apoptosis assay","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 2 — clean KD with defined cellular phenotype; 87 citations, foundational study","pmids":["15540201"],"is_preprint":false},{"year":2003,"finding":"PIM3 is a direct transcriptional target of EWS/ETS fusion oncoproteins; forced expression of PIM3 promotes anchorage-independent growth, and a kinase-deficient PIM3 mutant attenuates EWS/FLI1-mediated tumorigenesis, demonstrating that PIM3 kinase activity is required for its oncogenic function downstream of EWS/ETS.","method":"Microarray expression analysis, NIH 3T3 tumorigenesis assay, kinase-dead mutant overexpression, immunodeficient mouse model","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — kinase-dead mutagenesis plus in vivo rescue, 68 citations","pmids":["12748291"],"is_preprint":false},{"year":2009,"finding":"PIM3 phosphorylates the KSHV latency-associated nuclear antigen LANA at serine residues 205 and 206, counteracting LANA-mediated repression of KSHV lytic gene transcription and enabling viral reactivation.","method":"Co-immunoprecipitation, phosphorylation mapping, overexpression of Pim-1/Pim-3, analysis of KSHV lytic gene transcription","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — specific phosphorylation sites identified with functional consequence on viral transcription; 60 citations","pmids":["19266083"],"is_preprint":false},{"year":2007,"finding":"PIM3 expression is regulated by the LIF/gp130/STAT3 signaling pathway in mouse embryonic stem cells; PIM3 supports ES cell self-renewal and prevents apoptosis downstream of STAT3.","method":"Chimeric receptor system, hormone-dependent STAT3-ER construct, overexpression and shRNA knockdown, clonal self-renewal assay","journal":"Stem cells","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches establishing pathway position; 58 citations","pmids":["17717068"],"is_preprint":false},{"year":2008,"finding":"The transcription factor Ets-1 directly binds the 5'-flanking region of the human PIM3 gene (between -249 and -183 bp, with an Ets-1 binding site at -216 to -211 bp) and drives constitutive PIM3 expression in pancreatic cancer cells; Ets-1 knockdown reduces BAD phosphorylation at Ser112 and induces apoptosis, which is rescued by PIM3 cDNA overexpression.","method":"Luciferase reporter assay with deletion mutants, chromatin immunoprecipitation (ChIP), dominant-negative Ets-1, siRNA, Western blot, rescue experiment","journal":"Cancer science","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP, promoter deletion/mutagenesis, epistasis rescue; 36 citations","pmids":["19154409"],"is_preprint":false},{"year":2013,"finding":"Translationally controlled tumor protein (TCTP/TPT1) interacts with PIM3 through PIM3's C-terminal region and TCTP's N-terminal region, and stabilizes PIM3 protein via protection from ubiquitin-proteasome degradation; TCTP knockdown reduces PIM3 protein but not mRNA.","method":"Yeast 2-hybrid screen, Co-IP, mapping studies, RNAi, proteasome inhibitor assays, in vitro and in vivo tumor assays","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — yeast 2-hybrid plus Co-IP plus proteasome mechanism; 42 citations","pmids":["24165482"],"is_preprint":false},{"year":2011,"finding":"PIM3 is a direct c-Myc transcriptional target; c-Myc binds conserved E-boxes within the Pim3 gene, and Myc-transgenic mouse lymphomas as well as Burkitt lymphoma cell lines exhibit elevated Pim-3 levels.","method":"ChIP (c-Myc binding to Pim3 E-boxes), gene expression analysis in Myc-transgenic lymphomas and cell lines, pan-PIM inhibitor cell death assay","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating direct Myc binding plus in vivo evidence; 41 citations","pmids":["21646687"],"is_preprint":false},{"year":2009,"finding":"PIM3 is expressed in endothelial cells, localizes to lamellipodia and co-localizes with focal adhesion kinase (FAK); PIM3 is dispersed from lamellipodia by cytochalasin D (actin polymerization inhibitor), and siRNA knockdown of PIM3 impairs EC spreading, migration, proliferation, and tube formation on Matrigel.","method":"Immunofluorescence/co-localization, cytochalasin D treatment, siRNA knockdown, Matrigel tube formation assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 — localization tied to functional consequence, single lab; 31 citations","pmids":["19229879"],"is_preprint":false},{"year":2009,"finding":"PIM3 up-regulation via p38 MAPK signaling protects cardiomyocytes against anoxia/reoxygenation injury; inhibition of p38 MAPK by SB203580 abolishes both PIM3 up-regulation and anoxic preconditioning-mediated cardioprotection.","method":"Pim-3 expression vector transfection, p38 MAPK inhibitor SB203580, cardiomyocyte A/R model","journal":"International journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — epistasis via pharmacologic inhibition plus OE; single lab","pmids":["19505587"],"is_preprint":false},{"year":2010,"finding":"PIM3 overexpression in the liver accelerates hepatocellular carcinoma development induced by diethylnitrosamine but does not cause HCC alone, indicating PIM3 acts as a tumor promoter rather than initiator; transgenic hepatocytes show accelerated cell cycle progression.","method":"Liver-selective PIM3 transgenic mice, diethylnitrosamine treatment, histological analysis, PCNA/CD31 staining","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — in vivo transgenic model with carcinogen co-treatment; 56 citations","pmids":["20101231"],"is_preprint":false},{"year":2010,"finding":"PIM3 negatively regulates glucose-stimulated insulin secretion in pancreatic β-cells by inhibiting ERK1/2 activation through SOCS6; PIM3 physically interacts with SOCS6 and Pim3-/- islets show reduced SOCS6 and increased ERK1/2 phosphorylation, augmenting second-phase insulin secretion.","method":"Microarray on glucose-stimulated MIN6 cells, Pim3-/- knockout mice, Co-immunoprecipitation (PIM3-SOCS6 interaction), SOCS6 overexpression inhibition of ERK1/2, glucose tolerance test","journal":"Islets","confidence":"High","confidence_rationale":"Tier 2 — Co-IP binding partner, KO mouse phenotype, epistasis via SOCS6 OE; 16 citations","pmids":["21099329"],"is_preprint":false},{"year":2014,"finding":"PIM3 promotes pancreatic cancer angiogenesis in vivo through upregulation of VEGF; kinase-dead PIM3 (K69M) abolished enhanced Bad-Ser112 phosphorylation, angiogenesis, and tumor neovascularization, confirming kinase-activity dependence.","method":"Stable cell lines with WT vs K69M kinase-dead PIM3, nude mouse orthotopic xenograft, MRI tumor measurement, VEGF ELISA, CD31 staining","journal":"The Journal of surgical research / Oncology reports","confidence":"High","confidence_rationale":"Tier 2 — kinase-dead mutant plus in vivo xenograft; two related papers","pmids":["23845873","24789328"],"is_preprint":false},{"year":2017,"finding":"mTORC1 suppresses PIM3 expression via SREBP1/2-driven miR-33, which targets PIM3 mRNA; rapamycin (mTORC1 inhibitor) increases PIM3 transcript and protein, and this is dependent on reduced miR-33 expression.","method":"Rapamycin treatment, TSC knockout cells, miR-33 expression analysis, mTORC1 activation models in vivo (mouse liver feeding)","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple cell/mouse models but indirect mechanistic link via miRNA; 7 citations","pmids":["29167471","29170467"],"is_preprint":false},{"year":2015,"finding":"miR-33a directly targets the PIM3 3'-UTR to suppress PIM3 expression, leading to downregulation of the AKT/GSK-3β/β-catenin pathway and increased sensitivity to gemcitabine in pancreatic cancer cells.","method":"Luciferase reporter assay (miR-33a targeting PIM3 3'-UTR), miR-33a overexpression, Western blot for AKT/GSK-3β/β-catenin","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct 3'-UTR targeting validated by luciferase; pathway downstream less rigorously defined","pmids":["25971209"],"is_preprint":false},{"year":2018,"finding":"PIM3 promotes melanoma cell migration and invasion by phosphorylating/activating STAT3 (Tyr705), which induces expression of EMT factors Slug, Snail, and ZEB1.","method":"shRNA knockdown, tumor-bearing mouse model for lung metastasis, Western blot for pSTAT3","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2-3 — KD with defined pathway, single lab; mechanistic link to STAT3 phosphorylation shown","pmids":["29370558"],"is_preprint":false},{"year":2020,"finding":"PIM3 promotes cell migration in liver cancer by activating RhoA GTPase and regulating cytoskeletal rearrangements; quantitative phosphoproteomics revealed that PIM3 overexpression elevates phosphorylation of multiple Rho GTPase modulators targeting RhoA.","method":"Quantitative proteomics and phosphoproteomics, RhoA activity assay, cytoskeletal imaging, migration assay","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 2 — phosphoproteomics plus functional validation; single lab, 11 citations","pmids":["31994402"],"is_preprint":false},{"year":2022,"finding":"PIM3 suppresses the MuERVL-marked 2-cell-like state in embryonic stem cells via an AMPK-HDAC4/5 axis: loss of PIM3 leads to increased AMPK phosphorylation, which phosphorylates HDAC4/5, causing their nuclear export, reducing H3K9ac deacetylation and increasing H3K9ac/decreasing H3K9me1/2 on MuERVL, activating 2-cell genes.","method":"Pim3 KO ESCs, AMPK phosphorylation assay, HDAC4/5 nuclear localization, H3K9ac/H3K9me ChIP, PIM3 inhibitor treatment","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + epistasis + chromatin modification analysis; 10 citations","pmids":["36150380"],"is_preprint":false},{"year":2020,"finding":"PIM3 overexpression promotes AML cell migration via phosphorylation of CXCR4 at Ser339; PIM3 physically interacts with phosphorylated CXCR4, and PIM3-overexpressing AML cells show increased cell surface CXCR4 and chemotaxis.","method":"Co-immunoprecipitation (PIM3-pCXCR4), Western blot (pCXCR4-Ser339), cell migration assay, immunofluorescence","journal":"OncoTargets and therapy","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP with functional migration assay; single lab","pmids":["32764981"],"is_preprint":false},{"year":2022,"finding":"PIM3 promotes hepatoblastoma metastasis by upregulating cell surface expression and phosphorylation of CXCR4; CXCR4 blockade with AMD3100 decreased the metastatic phenotype of PIM3-overexpressing cells, establishing CXCR4 as a downstream effector of PIM3-driven metastasis.","method":"CRISPR/Cas9 PIM3 knockout, PIM3 overexpression, tail-vein injection metastasis model, AMD3100 CXCR4 inhibition, flow cytometry for cell surface CXCR4","journal":"Clinical & experimental metastasis","confidence":"High","confidence_rationale":"Tier 2 — CRISPR KO plus OE plus pharmacologic epistasis in vivo","pmids":["36315303"],"is_preprint":false},{"year":2021,"finding":"CRISPR/Cas9-mediated PIM3 knockout in hepatoblastoma cells decreases proliferation, viability, motility, and tumor growth in xenograft model, decreases tumorsphere formation and stemness markers including CD133, and reintroduction of PIM3 rescues the malignant phenotype.","method":"CRISPR/Cas9 dual-gRNA PIM3 knockout, xenograft, tumorsphere assay, RNA-seq, flow cytometry for CD133, PIM3 rescue","journal":"Cancer gene therapy","confidence":"High","confidence_rationale":"Tier 2 — CRISPR KO with rescue experiment and multiple orthogonal readouts","pmids":["33864024"],"is_preprint":false},{"year":2025,"finding":"PIM3 phosphorylates MLF2 at Ser65, enhancing MLF2 stabilization through USP21 interaction and preventing STUB1-mediated ubiquitination and proteasomal degradation; MLF2 stabilization activates the IRE1α/XBP1-S-MMP9 axis to promote osteosarcoma lung metastasis.","method":"In vivo CRISPR activation screen, Co-IP, phosphorylation site mapping, ubiquitination assay, STUB1 interaction assay, USP21 interaction assay","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — specific phosphorylation site (Ser65) identified mechanistically with multiple orthogonal binding/modification assays in high-impact journal","pmids":["41090348"],"is_preprint":false},{"year":2025,"finding":"PIM3 physically interacts with and activates the Akt signaling pathway in nucleus pulposus cells, regulating downstream mTOR and FoxO1 to maintain cell viability and suppress senescence; these effects require PIM3 kinase activity.","method":"Co-immunoprecipitation (PIM3-Akt), kinase-dead PIM3 experiments, Western blot for p-Akt/mTOR/FoxO1, AAV-mediated PIM3 overexpression in rat IDD model","journal":"Translational research","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP plus kinase-dead mutant plus in vivo AAV; single lab, new paper","pmids":["41478528"],"is_preprint":false},{"year":2017,"finding":"In HTLV-1-infected T cells, Tax induces PIM3 expression through NF-κB; PIM3 knockdown inhibits growth of HTLV-1-infected T cells, and a Pim-1/3 inhibitor induces G2/M arrest and apoptosis by downregulating cyclin A, cyclin B1, XIAP, and Mcl-1 through NF-κB pathway inhibition.","method":"siRNA knockdown, EMSA (NF-κB DNA binding), RT-PCR, cell cycle analysis, pharmacologic Pim-1/3 inhibitor","journal":"European journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2-3 — NF-κB pathway placement by EMSA and siRNA; single lab","pmids":["28833639"],"is_preprint":false},{"year":2016,"finding":"PIM3 promotes radioresistance in pancreatic cancer cells by attenuating G2/M cell cycle arrest and DNA damage response; PIM3 silencing increases γH2AX phosphorylation (DNA DSB marker) and decreases ATM kinase activation and its downstream targets.","method":"Stable PIM3 overexpression and siRNA knockdown, radiation treatment, γH2AX assay, ATM/downstream target Western blot, in vivo xenograft with radiation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — multiple mechanistic readouts linking PIM3 to DDR pathway; single lab","pmids":["27016481"],"is_preprint":false},{"year":2019,"finding":"Aldosterone stimulates PIM3 expression in the aldosterone-sensitive distal nephron in vitro, ex vivo, and in vivo; Pim3-/- mice show upregulated RAAS with high circulating aldosterone and plasma renin activity, and compensatory upregulation of PIM1 and PIM2 in kidney.","method":"Germline Pim3-/- knockout mice, mCCDcl1 cell aldosterone treatment, mouse kidney slice assays, RAAS measurement","journal":"Physiological reports","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse phenotype with multiple in vivo/ex vivo/in vitro validations; functional role of PIM3 itself in RAAS remains compensated","pmids":["31397090"],"is_preprint":false},{"year":2024,"finding":"Endothelial PIM3 protects the vascular barrier against metastatic colonization by maintaining junctional VE-cadherin (cadherin-5) and catenins α, β, and δ; PIM inhibition increases vascular leakage and metastatic colonization in lung.","method":"scRNA-seq of lung ECs, spontaneous metastasis models, PIM inhibitor treatment, junction protein Western blot/immunofluorescence, lung metastasis quantification","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — scRNA-seq plus pharmacologic inhibition with defined molecular mechanism in Nature Communications; 5 citations","pmids":["39627185"],"is_preprint":false},{"year":2019,"finding":"PIM3 promotes cholesterol-driven colorectal cancer cell proliferation and survival by phosphorylating p27, p21, and BAD; cholesterol suppresses miR-33a, leading to PIM3 upregulation, and miR-33a directly targets PIM3 as confirmed by dual luciferase reporter assay.","method":"Dual luciferase reporter assay, miR-33a mimics/inhibitor, Western blot for p27/p21/pBAD, CCK8, flow cytometry","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — luciferase validation plus substrate phosphorylation; single lab","pmids":["30827510"],"is_preprint":false},{"year":2017,"finding":"PIM3 regulates pancreatic cancer cell stemness via activating STAT3 signaling; PIM3 silencing decreases phosphorylation and transcriptional activity of STAT3, and STAT3 reactivation rescues the stem cell-like phenotype lost upon PIM3 knockdown.","method":"Pim-3 siRNA, CD24/ESA sorting for cancer stem cell subpopulations, STAT3 phosphorylation assay, STAT3 rescue experiment, tumorsphere and tumorigenicity assays","journal":"Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 — epistasis via STAT3 rescue; single lab; mechanism of STAT3 phosphorylation by PIM3 not directly demonstrated","pmids":["28775772"],"is_preprint":false},{"year":2025,"finding":"The natural compound CSH-4044 (isolated from fermented wheat germ extract) inhibits PIM3 kinase activity in an ATP-competitive manner (co-crystal structure with PIM1 determined), and suppresses PIM3-driven BAD phosphorylation at Ser112 in pancreatic cancer cells.","method":"X-ray crystallography (PIM1 co-crystal structure), kinase profiling, phospho-BAD Western blot in pancreatic cancer cells","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 — crystal structure plus in-cell pharmacodynamic assay; preprint, not yet peer-reviewed","pmids":[],"is_preprint":true},{"year":2023,"finding":"PIM3 phosphorylates MAPK1 at T185 and Y187 in esophageal squamous cell carcinoma cells to promote proliferation and tumor development; corynoline directly binds PIM3, inhibits its kinase activity, and suppresses ESCC growth.","method":"Pull-down assay, cellular thermal shift assay, kinase assay, phosphorylation site identification, patient-derived xenograft tumor model","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 2 — multiple direct binding/kinase assays; novel substrate (MAPK1 at T185/Y187) identified; single lab","pmids":["38128397"],"is_preprint":false},{"year":2025,"finding":"ETS1 transcription factor transcriptionally upregulates PIM3 in myocardial ischemia-reperfusion injury; hyperglycemia similarly drives nuclear translocation of YY1, which binds the PIM3 promoter and enhances PIM3 transcriptional activity, promoting cardiac hypertrophy.","method":"ChIP assay (YY1 binding to Pim3 promoter), luciferase reporter assay, ETS1/YY1 knockdown, mouse MIRI and diabetic models","journal":"Experimental cell research / Iranian journal of basic medical sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and luciferase for transcriptional regulation; two independent studies (ETS1 and YY1) both using ChIP","pmids":["40189183","39850120"],"is_preprint":false}],"current_model":"PIM3 is a constitutively active serine/threonine kinase (CaMK group) that promotes cell survival primarily by phosphorylating BAD at Ser112 to inactivate its pro-apoptotic function; it also phosphorylates LANA (enabling KSHV reactivation), MLF2 at Ser65 (promoting metastasis via IRE1α/XBP1-S-MMP9), MAPK1 at T185/Y187, and CXCR4 at Ser339, while activating downstream signaling through STAT3, RhoA/GTPase, and Akt/mTOR/FoxO1 axes; PIM3 expression is transcriptionally driven by Ets-1, c-Myc, STAT3, and YY1, and post-translationally stabilized by TCTP through protection from ubiquitin-proteasomal degradation, while being suppressed by mTORC1-driven miR-33."},"narrative":{"teleology":[{"year":2003,"claim":"Establishing that PIM3 is an oncogenic kinase: its identification as a transcriptional target of EWS/ETS fusions, combined with the finding that kinase-dead PIM3 suppresses transformation, demonstrated that PIM3 kinase activity is required for EWS/FLI1-driven tumorigenesis.","evidence":"Microarray, kinase-dead mutant (K69M) overexpression, NIH 3T3 soft agar and nude mouse tumorigenesis assays","pmids":["12748291"],"confidence":"High","gaps":["Direct phosphorylation substrates unidentified at this stage","Endogenous relevance beyond Ewing sarcoma unknown"]},{"year":2005,"claim":"Defining PIM3 as an anti-apoptotic, pro-proliferative kinase: siRNA-mediated knockdown in hepatoma cells showed PIM3 is required for cell survival, establishing its role in epithelial cancer beyond Ewing sarcoma.","evidence":"RNA interference in human hepatoma cell lines with proliferation and apoptosis assays","pmids":["15540201"],"confidence":"High","gaps":["Molecular substrates mediating anti-apoptotic effect unknown","In vivo relevance not yet tested"]},{"year":2006,"claim":"Identifying BAD Ser112 as the key pro-survival substrate: PIM3 directly phosphorylates BAD at Ser112 (not Ser136) to inactivate its pro-apoptotic function, providing the first defined substrate mechanism for PIM3-mediated survival signaling, replicated across pancreatic, colon, and liver cancer.","evidence":"shRNA knockdown, phospho-BAD Western blot, apoptosis assays in pancreatic and colon cancer cells; IHC co-localization in clinical tissues","pmids":["16818649","17270021"],"confidence":"High","gaps":["Whether BAD is the sole survival substrate unclear","Structural basis of PIM3-BAD interaction unresolved"]},{"year":2007,"claim":"Positioning PIM3 downstream of STAT3 in stem cell biology: PIM3 was shown to be a STAT3-regulated gene in ES cells that promotes self-renewal and prevents apoptosis, expanding its role beyond cancer to developmental biology.","evidence":"Chimeric gp130 receptor, STAT3-ER inducible system, shRNA knockdown, clonal self-renewal assay in mouse ESCs","pmids":["17717068"],"confidence":"High","gaps":["Direct STAT3 binding to PIM3 promoter not shown by ChIP in this study","Substrates mediating ES cell self-renewal undefined"]},{"year":2008,"claim":"Defining transcriptional regulation of PIM3: Ets-1 was shown to directly bind the PIM3 promoter and drive constitutive expression, with c-Myc later shown to bind E-boxes within the Pim3 gene, establishing PIM3 as a convergence point of multiple oncogenic transcription factors.","evidence":"ChIP, luciferase reporter with promoter deletions, epistasis rescue (Ets-1 KD rescued by PIM3 cDNA); ChIP for c-Myc on Pim3 E-boxes in Burkitt lymphoma","pmids":["19154409","21646687"],"confidence":"High","gaps":["Relative contribution of Ets-1 vs c-Myc vs STAT3 in different contexts not resolved","Chromatin-level regulation of PIM3 promoter accessibility unknown"]},{"year":2009,"claim":"Expanding PIM3 substrates to viral latency and revealing non-cancer functions: PIM3 phosphorylates KSHV LANA at Ser205/206 to relieve transcriptional repression and enable lytic reactivation; separately, PIM3 localizes to lamellipodia in endothelial cells and is required for EC migration and tube formation.","evidence":"Co-IP, phosphorylation mapping, lytic gene transcription analysis for LANA; immunofluorescence co-localization with FAK, siRNA, Matrigel assay for ECs","pmids":["19266083","19229879"],"confidence":"High","gaps":["Whether PIM3 kinase activity is directly required for lamellipodia localization unclear","In vivo relevance of PIM3 in angiogenesis not yet demonstrated"]},{"year":2010,"claim":"Demonstrating PIM3 as a tumor promoter in vivo and identifying a metabolic substrate: liver-specific PIM3 transgenic mice develop accelerated HCC only with carcinogen co-treatment, establishing PIM3 as a promoter not initiator; separately, PIM3 negatively regulates insulin secretion via SOCS6-mediated ERK1/2 inhibition in β-cells.","evidence":"Liver-selective transgenic mouse with DEN; Pim3-/- knockout mice with glucose tolerance testing, Co-IP of PIM3-SOCS6","pmids":["20101231","21099329"],"confidence":"High","gaps":["Direct phosphorylation of SOCS6 by PIM3 not demonstrated","Mechanism by which PIM3 accelerates cell cycle in hepatocytes beyond BAD unclear"]},{"year":2013,"claim":"Revealing post-translational control of PIM3 stability: TCTP/TPT1 physically interacts with PIM3's C-terminus and protects it from ubiquitin-proteasome degradation, establishing that PIM3 protein levels are controlled at the post-translational level in addition to transcriptional regulation.","evidence":"Yeast two-hybrid, Co-IP, domain mapping, proteasome inhibitor rescue, RNAi of TCTP","pmids":["24165482"],"confidence":"High","gaps":["E3 ligase responsible for PIM3 ubiquitination not identified","Whether TCTP-PIM3 interaction is regulated by signaling unknown"]},{"year":2015,"claim":"Identifying miR-33a as a negative regulator targeting PIM3 mRNA: miR-33a directly targets the PIM3 3′-UTR, and mTORC1 drives miR-33 expression via SREBP1/2, creating a feedback loop where mTORC1 activity suppresses PIM3.","evidence":"Dual luciferase reporter for 3′-UTR targeting; rapamycin treatment, TSC-null cells, in vivo mouse liver feeding model","pmids":["25971209","29167471"],"confidence":"Medium","gaps":["Functional importance of mTORC1-miR-33-PIM3 axis in specific disease contexts not established","Whether other miRNAs regulate PIM3 not explored systematically"]},{"year":2017,"claim":"Linking PIM3 to cancer stemness and STAT3-mediated EMT: PIM3 activates STAT3 phosphorylation to maintain pancreatic cancer stemness and promotes melanoma metastasis through STAT3-driven Slug/Snail/ZEB1 expression.","evidence":"siRNA with STAT3 rescue in pancreatic CSCs; shRNA with in vivo lung metastasis model in melanoma","pmids":["28775772","29370558"],"confidence":"Medium","gaps":["Whether PIM3 directly phosphorylates STAT3 or acts through an intermediary kinase not resolved","Mechanism of PIM3 selectivity for stem-like subpopulations undefined"]},{"year":2020,"claim":"Identifying RhoA and CXCR4 as PIM3-regulated effectors of cell migration: phosphoproteomics revealed PIM3 activates RhoA GTPase signaling for cytoskeletal rearrangement in liver cancer, and PIM3 phosphorylates CXCR4 at Ser339 to promote AML cell chemotaxis.","evidence":"Quantitative phosphoproteomics with RhoA activity assay; Co-IP of PIM3-pCXCR4 with migration assay","pmids":["31994402","32764981"],"confidence":"Medium","gaps":["Direct PIM3-RhoA phosphorylation event not identified","CXCR4 Ser339 phosphorylation by PIM3 shown by single Co-IP without in vitro kinase assay confirmation"]},{"year":2022,"claim":"Revealing a chromatin-regulatory role in totipotency suppression: PIM3 knockout in ESCs activates the MuERVL-marked 2-cell-like state through increased AMPK phosphorylation, nuclear export of HDAC4/5, and consequent H3K9 hyperacetylation on endogenous retroviral elements.","evidence":"Pim3 KO ESCs, AMPK phosphorylation analysis, HDAC4/5 localization, H3K9ac/me ChIP at MuERVL loci","pmids":["36150380"],"confidence":"High","gaps":["Whether PIM3 directly phosphorylates AMPK or suppresses its activation indirectly unknown","Relevance of this axis in preimplantation embryos in vivo not tested"]},{"year":2022,"claim":"Validating CXCR4 as an in vivo metastatic effector downstream of PIM3: CRISPR knockout and overexpression combined with pharmacologic CXCR4 blockade (AMD3100) in hepatoblastoma demonstrated PIM3-CXCR4 epistasis in metastatic colonization.","evidence":"CRISPR/Cas9 KO and OE, tail-vein metastasis model, AMD3100 rescue, flow cytometry for surface CXCR4","pmids":["36315303","33864024"],"confidence":"High","gaps":["Whether PIM3-CXCR4 axis operates in non-hepatoblastoma metastasis unknown","Contribution of CXCR4 phosphorylation vs. surface trafficking not disentangled"]},{"year":2024,"claim":"Uncovering a tumor-suppressive context: endothelial PIM3 maintains VE-cadherin-based adherens junctions to preserve vascular barrier integrity, and PIM inhibition paradoxically increases metastatic colonization by disrupting the endothelial barrier.","evidence":"scRNA-seq of lung ECs, spontaneous metastasis models, PIM inhibitor treatment, junction protein analysis","pmids":["39627185"],"confidence":"High","gaps":["Direct PIM3 substrate maintaining junctional stability not identified","Whether this barrier-protective role counteracts tumor-cell-intrinsic PIM3 oncogenic effects in clinical settings unknown"]},{"year":2025,"claim":"Identifying MLF2 Ser65 as a metastasis-promoting substrate and MAPK1 as a direct PIM3 substrate: PIM3 phosphorylates MLF2 at Ser65, stabilizing it via USP21 and activating the IRE1α/XBP1-S-MMP9 metastatic axis; separately, PIM3 phosphorylates MAPK1 at T185/Y187 to drive ESCC proliferation.","evidence":"CRISPR activation screen, Co-IP, phosphosite mapping, ubiquitination assay for MLF2; pull-down, CETSA, kinase assay for MAPK1 in PDX model","pmids":["41090348","38128397"],"confidence":"High","gaps":["Whether MLF2 phosphorylation is PIM3-specific or shared with PIM1/PIM2 not tested","Structural basis for PIM3 dual Ser/Thr and Tyr kinase activity on MAPK1 unresolved"]},{"year":null,"claim":"Key open questions include: the structural basis of PIM3 substrate selectivity, whether PIM3 directly phosphorylates STAT3 or AMPK, the identity of the E3 ligase that ubiquitinates PIM3, and how tumor-cell-intrinsic oncogenic activity is reconciled with endothelial barrier-protective functions in therapeutic targeting.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of PIM3 (only PIM1 co-crystal reported)","E3 ubiquitin ligase for PIM3 not identified","Context-dependent tumor-promoting vs. barrier-protective functions not reconciled mechanistically"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4,12,13,19,22,28,31]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[18,29]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[18]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,2,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,12,15,16,23,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,11,13,21,22,31]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[18]}],"complexes":[],"partners":["BAD","SOCS6","TCTP","CXCR4","MLF2","MAPK1","STAT3"],"other_free_text":[]},"mechanistic_narrative":"PIM3 is a constitutively active serine/threonine kinase of the CaMK group that functions as a pro-survival and pro-tumorigenic signaling node, integrating transcriptional inputs from ETS-family factors, c-Myc, STAT3, and YY1 with post-translational stabilization by TCTP to phosphorylate substrates that govern apoptosis, cell migration, stemness, and chromatin state [PMID:16818649, PMID:12748291, PMID:19154409, PMID:21646687, PMID:24165482, PMID:36150380]. Its best-characterized kinase activity is phosphorylation of the pro-apoptotic protein BAD at Ser112, which inactivates BAD and suppresses apoptosis across pancreatic, colon, and liver cancers; additional direct substrates include KSHV LANA (Ser205/206), MLF2 (Ser65), CXCR4 (Ser339), and MAPK1 (T185/Y187), linking PIM3 to viral reactivation, metastasis via the IRE1α/XBP1-S axis, chemokine receptor signaling, and MAPK pathway activation [PMID:16818649, PMID:19266083, PMID:41090348, PMID:36315303, PMID:38128397]. PIM3 also maintains endothelial barrier integrity by sustaining junctional VE-cadherin and catenin complexes, and in embryonic stem cells it suppresses the 2-cell-like totipotent state through an AMPK–HDAC4/5–H3K9ac chromatin axis [PMID:39627185, PMID:36150380]. Its expression is negatively regulated by mTORC1-driven miR-33a, which directly targets the PIM3 3′-UTR [PMID:29167471, PMID:25971209]."},"prefetch_data":{"uniprot":{"accession":"Q86V86","full_name":"Serine/threonine-protein kinase pim-3","aliases":[],"length_aa":326,"mass_kda":35.9,"function":"Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation. May contribute to tumorigenesis through: the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), the regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. Additionally to this role on tumorigenesis, can also negatively regulate insulin secretion by inhibiting the activation of MAPK1/3 (ERK1/2), through SOCS6. Involved also in the control of energy metabolism and regulation of AMPK activity in modulating MYC and PPARGC1A protein levels and cell growth","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q86V86/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PIM3","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PIM3","total_profiled":1310},"omim":[{"mim_id":"610580","title":"ONCOGENE PIM3; PIM3","url":"https://www.omim.org/entry/610580"},{"mim_id":"606232","title":"PHELAN-MCDERMID SYNDROME; PHMDS","url":"https://www.omim.org/entry/606232"},{"mim_id":"300295","title":"PIM2 PROTOONCOGENE, SERINE/THREONINE KINASE; PIM2","url":"https://www.omim.org/entry/300295"},{"mim_id":"164960","title":"ONCOGENE PIM 1; PIM1","url":"https://www.omim.org/entry/164960"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PIM3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q86V86","domains":[{"cath_id":"3.30.200.20","chopping":"38-125","consensus_level":"high","plddt":92.4706,"start":38,"end":125},{"cath_id":"1.10.510.10","chopping":"130-295","consensus_level":"high","plddt":97.413,"start":130,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86V86","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86V86-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86V86-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PIM3","jax_strain_url":"https://www.jax.org/strain/search?query=PIM3"},"sequence":{"accession":"Q86V86","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86V86.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86V86/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86V86"}},"corpus_meta":[{"pmid":"16818649","id":"PMC_16818649","title":"Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16818649","citation_count":156,"is_preprint":false},{"pmid":"17270021","id":"PMC_17270021","title":"Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.","date":"2007","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/17270021","citation_count":109,"is_preprint":false},{"pmid":"15540201","id":"PMC_15540201","title":"Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15540201","citation_count":87,"is_preprint":false},{"pmid":"22727640","id":"PMC_22727640","title":"Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.","date":"2012","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/22727640","citation_count":83,"is_preprint":false},{"pmid":"21518143","id":"PMC_21518143","title":"Roles of Pim-3, a novel survival kinase, in tumorigenesis.","date":"2011","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/21518143","citation_count":74,"is_preprint":false},{"pmid":"12748291","id":"PMC_12748291","title":"PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12748291","citation_count":68,"is_preprint":false},{"pmid":"17876606","id":"PMC_17876606","title":"Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.","date":"2007","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17876606","citation_count":66,"is_preprint":false},{"pmid":"25971209","id":"PMC_25971209","title":"MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25971209","citation_count":63,"is_preprint":false},{"pmid":"19266083","id":"PMC_19266083","title":"KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA.","date":"2009","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/19266083","citation_count":60,"is_preprint":false},{"pmid":"17717068","id":"PMC_17717068","title":"Self-renewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-3.","date":"2007","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/17717068","citation_count":58,"is_preprint":false},{"pmid":"20101231","id":"PMC_20101231","title":"Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20101231","citation_count":56,"is_preprint":false},{"pmid":"30827510","id":"PMC_30827510","title":"Cholesterol regulates cell proliferation and apoptosis of colorectal cancer by modulating miR-33a-PIM3 pathway.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30827510","citation_count":45,"is_preprint":false},{"pmid":"24165482","id":"PMC_24165482","title":"A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression.","date":"2013","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/24165482","citation_count":42,"is_preprint":false},{"pmid":"21646687","id":"PMC_21646687","title":"The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.","date":"2011","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/21646687","citation_count":41,"is_preprint":false},{"pmid":"21945284","id":"PMC_21945284","title":"Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases.","date":"2011","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/21945284","citation_count":40,"is_preprint":false},{"pmid":"27638830","id":"PMC_27638830","title":"MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27638830","citation_count":40,"is_preprint":false},{"pmid":"19154409","id":"PMC_19154409","title":"Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19154409","citation_count":36,"is_preprint":false},{"pmid":"25071334","id":"PMC_25071334","title":"Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.","date":"2014","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25071334","citation_count":34,"is_preprint":false},{"pmid":"19229879","id":"PMC_19229879","title":"Pim-3 is expressed in endothelial cells and promotes vascular tube formation.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19229879","citation_count":31,"is_preprint":false},{"pmid":"23760491","id":"PMC_23760491","title":"Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.","date":"2013","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23760491","citation_count":29,"is_preprint":false},{"pmid":"19505587","id":"PMC_19505587","title":"Pim-3 protects against cardiomyocyte apoptosis in anoxia/reoxygenation injury via p38-mediated signal pathway.","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19505587","citation_count":27,"is_preprint":false},{"pmid":"29370558","id":"PMC_29370558","title":"Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29370558","citation_count":26,"is_preprint":false},{"pmid":"29069816","id":"PMC_29069816","title":"Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29069816","citation_count":26,"is_preprint":false},{"pmid":"27016481","id":"PMC_27016481","title":"Pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27016481","citation_count":21,"is_preprint":false},{"pmid":"26238203","id":"PMC_26238203","title":"MicroRNA‑506 participates in pancreatic cancer pathogenesis by targeting PIM3.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26238203","citation_count":20,"is_preprint":false},{"pmid":"24789328","id":"PMC_24789328","title":"Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24789328","citation_count":20,"is_preprint":false},{"pmid":"31260686","id":"PMC_31260686","title":"Bufothionine exerts anti-cancer activities in gastric cancer through Pim3.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31260686","citation_count":19,"is_preprint":false},{"pmid":"25921139","id":"PMC_25921139","title":"Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells.","date":"2015","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25921139","citation_count":18,"is_preprint":false},{"pmid":"30654529","id":"PMC_30654529","title":"AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30654529","citation_count":18,"is_preprint":false},{"pmid":"24488669","id":"PMC_24488669","title":"Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24488669","citation_count":17,"is_preprint":false},{"pmid":"20039932","id":"PMC_20039932","title":"Pim-3 protects against hepatic failure in D-galactosamine (D-GalN)-sensitized rats.","date":"2009","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20039932","citation_count":17,"is_preprint":false},{"pmid":"21099329","id":"PMC_21099329","title":"Pim3 negatively regulates glucose-stimulated insulin secretion.","date":"2010","source":"Islets","url":"https://pubmed.ncbi.nlm.nih.gov/21099329","citation_count":16,"is_preprint":false},{"pmid":"33864024","id":"PMC_33864024","title":"CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.","date":"2021","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33864024","citation_count":15,"is_preprint":false},{"pmid":"15820782","id":"PMC_15820782","title":"Association of the PIM3 allele of the alpha-1-antitrypsin gene with chronic obstructive pulmonary disease.","date":"2005","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15820782","citation_count":15,"is_preprint":false},{"pmid":"23845873","id":"PMC_23845873","title":"Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor.","date":"2013","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/23845873","citation_count":15,"is_preprint":false},{"pmid":"29167471","id":"PMC_29167471","title":"Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29167471","citation_count":14,"is_preprint":false},{"pmid":"32764981","id":"PMC_32764981","title":"PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32764981","citation_count":13,"is_preprint":false},{"pmid":"25817345","id":"PMC_25817345","title":"Knockdown of Pim-3 suppresses the tumorigenicity of glioblastoma by regulating cell cycle and apoptosis.","date":"2015","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/25817345","citation_count":13,"is_preprint":false},{"pmid":"31994402","id":"PMC_31994402","title":"Proto-Oncogene Serine/Threonine Kinase PIM3 Promotes Cell Migration via Modulating Rho GTPase Signaling.","date":"2020","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/31994402","citation_count":11,"is_preprint":false},{"pmid":"38339286","id":"PMC_38339286","title":"PIM3 Kinase: A Promising Novel Target in Solid Cancers.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38339286","citation_count":11,"is_preprint":false},{"pmid":"30898394","id":"PMC_30898394","title":"The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.","date":"2019","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/30898394","citation_count":11,"is_preprint":false},{"pmid":"19624871","id":"PMC_19624871","title":"[Effect of ginsenoside Rg3 on Pim-3 and Bad proteins in human pancreatic cancer cell line PANC-1].","date":"2009","source":"Ai zheng = Aizheng = Chinese journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19624871","citation_count":11,"is_preprint":false},{"pmid":"30417983","id":"PMC_30417983","title":"PIM3 Functions as Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer.","date":"2018","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/30417983","citation_count":10,"is_preprint":false},{"pmid":"36150380","id":"PMC_36150380","title":"PIM3-AMPK-HDAC4/5 axis restricts MuERVL-marked 2-cell-like state in embryonic stem cells.","date":"2022","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36150380","citation_count":10,"is_preprint":false},{"pmid":"26547690","id":"PMC_26547690","title":"Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.","date":"2015","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/26547690","citation_count":10,"is_preprint":false},{"pmid":"28775772","id":"PMC_28775772","title":"Pim-3 Regulates Stemness of Pancreatic Cancer Cells via Activating STAT3 Signaling Pathway.","date":"2017","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28775772","citation_count":10,"is_preprint":false},{"pmid":"38002822","id":"PMC_38002822","title":"Predictive Value of PRISM-4, PIM-3, CRP, Albumin, CRP/Albumin Ratio and Lactate in Critically Ill Children.","date":"2023","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38002822","citation_count":7,"is_preprint":false},{"pmid":"29170467","id":"PMC_29170467","title":"mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29170467","citation_count":7,"is_preprint":false},{"pmid":"26269675","id":"PMC_26269675","title":"Overexpression of pim-3 and protective role in lipopolysaccharide-stimulated hepatic stellate cells.","date":"2015","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26269675","citation_count":7,"is_preprint":false},{"pmid":"32504181","id":"PMC_32504181","title":"High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms.","date":"2020","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32504181","citation_count":7,"is_preprint":false},{"pmid":"38128397","id":"PMC_38128397","title":"Corynoline inhibits esophageal squamous cell carcinoma growth via targeting Pim-3.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38128397","citation_count":7,"is_preprint":false},{"pmid":"31882428","id":"PMC_31882428","title":"Effect of Pim-3 Downregulation on Proliferation and Apoptosis in Lung Adenocarcinoma A549 Cells.","date":"2019","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/31882428","citation_count":7,"is_preprint":false},{"pmid":"26529487","id":"PMC_26529487","title":"Binding site identification and role of permanent water molecule of PIM-3 kinase: A molecular dynamics study.","date":"2015","source":"Journal of molecular graphics & modelling","url":"https://pubmed.ncbi.nlm.nih.gov/26529487","citation_count":7,"is_preprint":false},{"pmid":"24600488","id":"PMC_24600488","title":"Serine threonine kinase Pim-3 regulates STAT3 pathway to inhibit proliferation of human liver cancers.","date":"2014","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24600488","citation_count":6,"is_preprint":false},{"pmid":"31777546","id":"PMC_31777546","title":"Pim-3 alleviates lipopolysaccharide-stimulated AR42J pancreatic acinar cell injury via improving the inflammatory microenvironment.","date":"2019","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31777546","citation_count":6,"is_preprint":false},{"pmid":"28833639","id":"PMC_28833639","title":"Expression and significance of Pim-3 kinase in adult T-cell leukemia.","date":"2017","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/28833639","citation_count":6,"is_preprint":false},{"pmid":"28214201","id":"PMC_28214201","title":"Up-regulation of Pim-3 in Chronic Obstructive Pulmonary Disease (COPD) patients and its potential therapeutic role in COPD rat modeling.","date":"2017","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/28214201","citation_count":6,"is_preprint":false},{"pmid":"34468207","id":"PMC_34468207","title":"LncRNA RGMB-AS1 facilitates pancreatic cancer cell proliferation and migration but inhibits cell apoptosis via miR-574-3p/PIM3 axis.","date":"2021","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34468207","citation_count":6,"is_preprint":false},{"pmid":"39627185","id":"PMC_39627185","title":"Endothelial Pim3 kinase protects the vascular barrier during lung metastasis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39627185","citation_count":5,"is_preprint":false},{"pmid":"36315303","id":"PMC_36315303","title":"PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.","date":"2022","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/36315303","citation_count":5,"is_preprint":false},{"pmid":"38148455","id":"PMC_38148455","title":"PIM3 regulates myocardial ischemia/reperfusion injury via ferroptosis.","date":"2023","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38148455","citation_count":5,"is_preprint":false},{"pmid":"31628693","id":"PMC_31628693","title":"Downregulation of microRNA-124 prevents the development of acute liver failure through the upregulation of PIM-3.","date":"2019","source":"Experimental physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31628693","citation_count":5,"is_preprint":false},{"pmid":"31397090","id":"PMC_31397090","title":"The serine-threonine kinase PIM3 is an aldosterone-regulated protein in the distal nephron.","date":"2019","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/31397090","citation_count":4,"is_preprint":false},{"pmid":"41199316","id":"PMC_41199316","title":"Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41199316","citation_count":4,"is_preprint":false},{"pmid":"35722357","id":"PMC_35722357","title":"Long non-coding RNA (FALEC) promotes malignant behaviors of gastric cancer cells by regulating miR-203b/PIM3 axis.","date":"2022","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35722357","citation_count":4,"is_preprint":false},{"pmid":"35845311","id":"PMC_35845311","title":"Multi-stage analysis of FOXM1, PYROXD1, hTERT, PPARA, PIM3, BMI1 and MCTP1 expression patterns in colorectal cancer.","date":"2022","source":"Gastroenterology and hepatology from bed to bench","url":"https://pubmed.ncbi.nlm.nih.gov/35845311","citation_count":4,"is_preprint":false},{"pmid":"35338769","id":"PMC_35338769","title":"Long non-coding RNA long intergenic non-protein coding RNA 1232 promotes cell proliferation, migration and invasion in bladder cancer via modulating miR-370-5p/PIM3 axis.","date":"2022","source":"Journal of tissue engineering and regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35338769","citation_count":4,"is_preprint":false},{"pmid":"40189183","id":"PMC_40189183","title":"ETS1 modulates ferroptosis to affect the process of myocardial ischemia-reperfusion injury via PIM3.","date":"2025","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/40189183","citation_count":3,"is_preprint":false},{"pmid":"39507762","id":"PMC_39507762","title":"Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39507762","citation_count":3,"is_preprint":false},{"pmid":"18261321","id":"PMC_18261321","title":"[Protective role of Pim-3 gene in intestinal mucosa damaged by burn or lipopolysaccharide].","date":"2007","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/18261321","citation_count":3,"is_preprint":false},{"pmid":"8666412","id":"PMC_8666412","title":"Low frequency of PIM3 gene in patients with monoclonal gammopathies.","date":"1996","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/8666412","citation_count":1,"is_preprint":false},{"pmid":"37248373","id":"PMC_37248373","title":"LncRNA SNHG1 Accelerates Cell Proliferation, Migration, and Invasion of Hepatoblastoma Through Mediating miR-6838-5p/PIM3/RhoA Axis.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37248373","citation_count":1,"is_preprint":false},{"pmid":"39850120","id":"PMC_39850120","title":"Pim3 up-regulation by YY1 contributes to diabetes-induced cardiac hypertrophy and heart failure.","date":"2025","source":"Iranian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39850120","citation_count":1,"is_preprint":false},{"pmid":"27150984","id":"PMC_27150984","title":"[Expression and Significance of Pim-3 Gene in Acute Myeloid Leukemia].","date":"2016","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/27150984","citation_count":1,"is_preprint":false},{"pmid":"38199328","id":"PMC_38199328","title":"Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3.","date":"2024","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/38199328","citation_count":1,"is_preprint":false},{"pmid":"30481923","id":"PMC_30481923","title":"[Effects of endotoxin/lipopolysaccharide on early apoptosis of human neutrophil through PIM3].","date":"2018","source":"Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns","url":"https://pubmed.ncbi.nlm.nih.gov/30481923","citation_count":1,"is_preprint":false},{"pmid":"38106118","id":"PMC_38106118","title":"Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38106118","citation_count":1,"is_preprint":false},{"pmid":"23207234","id":"PMC_23207234","title":"[Inhibitive mechanisms of Pim-3 affecting fulminant hepatic apoptosis].","date":"2012","source":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/23207234","citation_count":1,"is_preprint":false},{"pmid":"41090348","id":"PMC_41090348","title":"PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/41090348","citation_count":0,"is_preprint":false},{"pmid":"41478528","id":"PMC_41478528","title":"PIM3 enhances nucleus pulposus cell function and extracellular matrix integrity via kinase-dependent activation of the Akt/mTOR signaling axis in intervertebral disc degeneration.","date":"2025","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41478528","citation_count":0,"is_preprint":false},{"pmid":"18067836","id":"PMC_18067836","title":"[Construction of a recombinant Pim3-expressing plasmid and expression and activity thereof: experiment with rats].","date":"2007","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/18067836","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.22.683941","title":"Identification and Validation of an inhibitor of the protein kinases PIM and DYRK","date":"2025-10-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.22.683941","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44456,"output_tokens":7557,"usd":0.123361},"stage2":{"model":"claude-opus-4-6","input_tokens":11336,"output_tokens":4282,"usd":0.245595},"total_usd":0.368956,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"PIM3 phosphorylates the pro-apoptotic protein BAD at Ser112 (but not Ser136) to inactivate it and prevent apoptosis in human pancreatic cancer cells; knockdown of PIM3 reduced BAD phosphorylation at Ser112 and Bcl-XL expression, promoting apoptosis.\",\n      \"method\": \"shRNA knockdown, Western blot for phospho-BAD (Ser112/Ser136), sub-G1 cell cycle analysis, phosphatidylserine externalization assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across multiple cancer types (pancreas, colon, liver) with orthogonal methods; foundational study with 156 citations\",\n      \"pmids\": [\"16818649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PIM3 phosphorylates BAD at Ser112 in human colon cancer cells, and PIM3 co-localizes with phospho-Ser112-BAD in clinical colon cancer tissues, inactivating BAD to prevent apoptosis.\",\n      \"method\": \"shRNA knockdown, Western blot, immunohistochemistry co-localization\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — independent replication of BAD-Ser112 phosphorylation mechanism in a second cancer type\",\n      \"pmids\": [\"17270021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PIM3 promotes hepatoma cell proliferation and prevents apoptosis; siRNA-mediated ablation of PIM3 attenuates proliferation and enhances apoptosis in human hepatoma cell lines.\",\n      \"method\": \"RNA interference, cell proliferation assay, apoptosis assay\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined cellular phenotype; 87 citations, foundational study\",\n      \"pmids\": [\"15540201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PIM3 is a direct transcriptional target of EWS/ETS fusion oncoproteins; forced expression of PIM3 promotes anchorage-independent growth, and a kinase-deficient PIM3 mutant attenuates EWS/FLI1-mediated tumorigenesis, demonstrating that PIM3 kinase activity is required for its oncogenic function downstream of EWS/ETS.\",\n      \"method\": \"Microarray expression analysis, NIH 3T3 tumorigenesis assay, kinase-dead mutant overexpression, immunodeficient mouse model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — kinase-dead mutagenesis plus in vivo rescue, 68 citations\",\n      \"pmids\": [\"12748291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PIM3 phosphorylates the KSHV latency-associated nuclear antigen LANA at serine residues 205 and 206, counteracting LANA-mediated repression of KSHV lytic gene transcription and enabling viral reactivation.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation mapping, overexpression of Pim-1/Pim-3, analysis of KSHV lytic gene transcription\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific phosphorylation sites identified with functional consequence on viral transcription; 60 citations\",\n      \"pmids\": [\"19266083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PIM3 expression is regulated by the LIF/gp130/STAT3 signaling pathway in mouse embryonic stem cells; PIM3 supports ES cell self-renewal and prevents apoptosis downstream of STAT3.\",\n      \"method\": \"Chimeric receptor system, hormone-dependent STAT3-ER construct, overexpression and shRNA knockdown, clonal self-renewal assay\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches establishing pathway position; 58 citations\",\n      \"pmids\": [\"17717068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The transcription factor Ets-1 directly binds the 5'-flanking region of the human PIM3 gene (between -249 and -183 bp, with an Ets-1 binding site at -216 to -211 bp) and drives constitutive PIM3 expression in pancreatic cancer cells; Ets-1 knockdown reduces BAD phosphorylation at Ser112 and induces apoptosis, which is rescued by PIM3 cDNA overexpression.\",\n      \"method\": \"Luciferase reporter assay with deletion mutants, chromatin immunoprecipitation (ChIP), dominant-negative Ets-1, siRNA, Western blot, rescue experiment\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP, promoter deletion/mutagenesis, epistasis rescue; 36 citations\",\n      \"pmids\": [\"19154409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Translationally controlled tumor protein (TCTP/TPT1) interacts with PIM3 through PIM3's C-terminal region and TCTP's N-terminal region, and stabilizes PIM3 protein via protection from ubiquitin-proteasome degradation; TCTP knockdown reduces PIM3 protein but not mRNA.\",\n      \"method\": \"Yeast 2-hybrid screen, Co-IP, mapping studies, RNAi, proteasome inhibitor assays, in vitro and in vivo tumor assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — yeast 2-hybrid plus Co-IP plus proteasome mechanism; 42 citations\",\n      \"pmids\": [\"24165482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PIM3 is a direct c-Myc transcriptional target; c-Myc binds conserved E-boxes within the Pim3 gene, and Myc-transgenic mouse lymphomas as well as Burkitt lymphoma cell lines exhibit elevated Pim-3 levels.\",\n      \"method\": \"ChIP (c-Myc binding to Pim3 E-boxes), gene expression analysis in Myc-transgenic lymphomas and cell lines, pan-PIM inhibitor cell death assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct Myc binding plus in vivo evidence; 41 citations\",\n      \"pmids\": [\"21646687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PIM3 is expressed in endothelial cells, localizes to lamellipodia and co-localizes with focal adhesion kinase (FAK); PIM3 is dispersed from lamellipodia by cytochalasin D (actin polymerization inhibitor), and siRNA knockdown of PIM3 impairs EC spreading, migration, proliferation, and tube formation on Matrigel.\",\n      \"method\": \"Immunofluorescence/co-localization, cytochalasin D treatment, siRNA knockdown, Matrigel tube formation assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — localization tied to functional consequence, single lab; 31 citations\",\n      \"pmids\": [\"19229879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PIM3 up-regulation via p38 MAPK signaling protects cardiomyocytes against anoxia/reoxygenation injury; inhibition of p38 MAPK by SB203580 abolishes both PIM3 up-regulation and anoxic preconditioning-mediated cardioprotection.\",\n      \"method\": \"Pim-3 expression vector transfection, p38 MAPK inhibitor SB203580, cardiomyocyte A/R model\",\n      \"journal\": \"International journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — epistasis via pharmacologic inhibition plus OE; single lab\",\n      \"pmids\": [\"19505587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM3 overexpression in the liver accelerates hepatocellular carcinoma development induced by diethylnitrosamine but does not cause HCC alone, indicating PIM3 acts as a tumor promoter rather than initiator; transgenic hepatocytes show accelerated cell cycle progression.\",\n      \"method\": \"Liver-selective PIM3 transgenic mice, diethylnitrosamine treatment, histological analysis, PCNA/CD31 staining\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with carcinogen co-treatment; 56 citations\",\n      \"pmids\": [\"20101231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM3 negatively regulates glucose-stimulated insulin secretion in pancreatic β-cells by inhibiting ERK1/2 activation through SOCS6; PIM3 physically interacts with SOCS6 and Pim3-/- islets show reduced SOCS6 and increased ERK1/2 phosphorylation, augmenting second-phase insulin secretion.\",\n      \"method\": \"Microarray on glucose-stimulated MIN6 cells, Pim3-/- knockout mice, Co-immunoprecipitation (PIM3-SOCS6 interaction), SOCS6 overexpression inhibition of ERK1/2, glucose tolerance test\",\n      \"journal\": \"Islets\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP binding partner, KO mouse phenotype, epistasis via SOCS6 OE; 16 citations\",\n      \"pmids\": [\"21099329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PIM3 promotes pancreatic cancer angiogenesis in vivo through upregulation of VEGF; kinase-dead PIM3 (K69M) abolished enhanced Bad-Ser112 phosphorylation, angiogenesis, and tumor neovascularization, confirming kinase-activity dependence.\",\n      \"method\": \"Stable cell lines with WT vs K69M kinase-dead PIM3, nude mouse orthotopic xenograft, MRI tumor measurement, VEGF ELISA, CD31 staining\",\n      \"journal\": \"The Journal of surgical research / Oncology reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — kinase-dead mutant plus in vivo xenograft; two related papers\",\n      \"pmids\": [\"23845873\", \"24789328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"mTORC1 suppresses PIM3 expression via SREBP1/2-driven miR-33, which targets PIM3 mRNA; rapamycin (mTORC1 inhibitor) increases PIM3 transcript and protein, and this is dependent on reduced miR-33 expression.\",\n      \"method\": \"Rapamycin treatment, TSC knockout cells, miR-33 expression analysis, mTORC1 activation models in vivo (mouse liver feeding)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple cell/mouse models but indirect mechanistic link via miRNA; 7 citations\",\n      \"pmids\": [\"29167471\", \"29170467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-33a directly targets the PIM3 3'-UTR to suppress PIM3 expression, leading to downregulation of the AKT/GSK-3β/β-catenin pathway and increased sensitivity to gemcitabine in pancreatic cancer cells.\",\n      \"method\": \"Luciferase reporter assay (miR-33a targeting PIM3 3'-UTR), miR-33a overexpression, Western blot for AKT/GSK-3β/β-catenin\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct 3'-UTR targeting validated by luciferase; pathway downstream less rigorously defined\",\n      \"pmids\": [\"25971209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PIM3 promotes melanoma cell migration and invasion by phosphorylating/activating STAT3 (Tyr705), which induces expression of EMT factors Slug, Snail, and ZEB1.\",\n      \"method\": \"shRNA knockdown, tumor-bearing mouse model for lung metastasis, Western blot for pSTAT3\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KD with defined pathway, single lab; mechanistic link to STAT3 phosphorylation shown\",\n      \"pmids\": [\"29370558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PIM3 promotes cell migration in liver cancer by activating RhoA GTPase and regulating cytoskeletal rearrangements; quantitative phosphoproteomics revealed that PIM3 overexpression elevates phosphorylation of multiple Rho GTPase modulators targeting RhoA.\",\n      \"method\": \"Quantitative proteomics and phosphoproteomics, RhoA activity assay, cytoskeletal imaging, migration assay\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphoproteomics plus functional validation; single lab, 11 citations\",\n      \"pmids\": [\"31994402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIM3 suppresses the MuERVL-marked 2-cell-like state in embryonic stem cells via an AMPK-HDAC4/5 axis: loss of PIM3 leads to increased AMPK phosphorylation, which phosphorylates HDAC4/5, causing their nuclear export, reducing H3K9ac deacetylation and increasing H3K9ac/decreasing H3K9me1/2 on MuERVL, activating 2-cell genes.\",\n      \"method\": \"Pim3 KO ESCs, AMPK phosphorylation assay, HDAC4/5 nuclear localization, H3K9ac/H3K9me ChIP, PIM3 inhibitor treatment\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + epistasis + chromatin modification analysis; 10 citations\",\n      \"pmids\": [\"36150380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PIM3 overexpression promotes AML cell migration via phosphorylation of CXCR4 at Ser339; PIM3 physically interacts with phosphorylated CXCR4, and PIM3-overexpressing AML cells show increased cell surface CXCR4 and chemotaxis.\",\n      \"method\": \"Co-immunoprecipitation (PIM3-pCXCR4), Western blot (pCXCR4-Ser339), cell migration assay, immunofluorescence\",\n      \"journal\": \"OncoTargets and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with functional migration assay; single lab\",\n      \"pmids\": [\"32764981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIM3 promotes hepatoblastoma metastasis by upregulating cell surface expression and phosphorylation of CXCR4; CXCR4 blockade with AMD3100 decreased the metastatic phenotype of PIM3-overexpressing cells, establishing CXCR4 as a downstream effector of PIM3-driven metastasis.\",\n      \"method\": \"CRISPR/Cas9 PIM3 knockout, PIM3 overexpression, tail-vein injection metastasis model, AMD3100 CXCR4 inhibition, flow cytometry for cell surface CXCR4\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO plus OE plus pharmacologic epistasis in vivo\",\n      \"pmids\": [\"36315303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CRISPR/Cas9-mediated PIM3 knockout in hepatoblastoma cells decreases proliferation, viability, motility, and tumor growth in xenograft model, decreases tumorsphere formation and stemness markers including CD133, and reintroduction of PIM3 rescues the malignant phenotype.\",\n      \"method\": \"CRISPR/Cas9 dual-gRNA PIM3 knockout, xenograft, tumorsphere assay, RNA-seq, flow cytometry for CD133, PIM3 rescue\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with rescue experiment and multiple orthogonal readouts\",\n      \"pmids\": [\"33864024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PIM3 phosphorylates MLF2 at Ser65, enhancing MLF2 stabilization through USP21 interaction and preventing STUB1-mediated ubiquitination and proteasomal degradation; MLF2 stabilization activates the IRE1α/XBP1-S-MMP9 axis to promote osteosarcoma lung metastasis.\",\n      \"method\": \"In vivo CRISPR activation screen, Co-IP, phosphorylation site mapping, ubiquitination assay, STUB1 interaction assay, USP21 interaction assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — specific phosphorylation site (Ser65) identified mechanistically with multiple orthogonal binding/modification assays in high-impact journal\",\n      \"pmids\": [\"41090348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PIM3 physically interacts with and activates the Akt signaling pathway in nucleus pulposus cells, regulating downstream mTOR and FoxO1 to maintain cell viability and suppress senescence; these effects require PIM3 kinase activity.\",\n      \"method\": \"Co-immunoprecipitation (PIM3-Akt), kinase-dead PIM3 experiments, Western blot for p-Akt/mTOR/FoxO1, AAV-mediated PIM3 overexpression in rat IDD model\",\n      \"journal\": \"Translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus kinase-dead mutant plus in vivo AAV; single lab, new paper\",\n      \"pmids\": [\"41478528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In HTLV-1-infected T cells, Tax induces PIM3 expression through NF-κB; PIM3 knockdown inhibits growth of HTLV-1-infected T cells, and a Pim-1/3 inhibitor induces G2/M arrest and apoptosis by downregulating cyclin A, cyclin B1, XIAP, and Mcl-1 through NF-κB pathway inhibition.\",\n      \"method\": \"siRNA knockdown, EMSA (NF-κB DNA binding), RT-PCR, cell cycle analysis, pharmacologic Pim-1/3 inhibitor\",\n      \"journal\": \"European journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — NF-κB pathway placement by EMSA and siRNA; single lab\",\n      \"pmids\": [\"28833639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PIM3 promotes radioresistance in pancreatic cancer cells by attenuating G2/M cell cycle arrest and DNA damage response; PIM3 silencing increases γH2AX phosphorylation (DNA DSB marker) and decreases ATM kinase activation and its downstream targets.\",\n      \"method\": \"Stable PIM3 overexpression and siRNA knockdown, radiation treatment, γH2AX assay, ATM/downstream target Western blot, in vivo xenograft with radiation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic readouts linking PIM3 to DDR pathway; single lab\",\n      \"pmids\": [\"27016481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Aldosterone stimulates PIM3 expression in the aldosterone-sensitive distal nephron in vitro, ex vivo, and in vivo; Pim3-/- mice show upregulated RAAS with high circulating aldosterone and plasma renin activity, and compensatory upregulation of PIM1 and PIM2 in kidney.\",\n      \"method\": \"Germline Pim3-/- knockout mice, mCCDcl1 cell aldosterone treatment, mouse kidney slice assays, RAAS measurement\",\n      \"journal\": \"Physiological reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse phenotype with multiple in vivo/ex vivo/in vitro validations; functional role of PIM3 itself in RAAS remains compensated\",\n      \"pmids\": [\"31397090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Endothelial PIM3 protects the vascular barrier against metastatic colonization by maintaining junctional VE-cadherin (cadherin-5) and catenins α, β, and δ; PIM inhibition increases vascular leakage and metastatic colonization in lung.\",\n      \"method\": \"scRNA-seq of lung ECs, spontaneous metastasis models, PIM inhibitor treatment, junction protein Western blot/immunofluorescence, lung metastasis quantification\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq plus pharmacologic inhibition with defined molecular mechanism in Nature Communications; 5 citations\",\n      \"pmids\": [\"39627185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PIM3 promotes cholesterol-driven colorectal cancer cell proliferation and survival by phosphorylating p27, p21, and BAD; cholesterol suppresses miR-33a, leading to PIM3 upregulation, and miR-33a directly targets PIM3 as confirmed by dual luciferase reporter assay.\",\n      \"method\": \"Dual luciferase reporter assay, miR-33a mimics/inhibitor, Western blot for p27/p21/pBAD, CCK8, flow cytometry\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — luciferase validation plus substrate phosphorylation; single lab\",\n      \"pmids\": [\"30827510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PIM3 regulates pancreatic cancer cell stemness via activating STAT3 signaling; PIM3 silencing decreases phosphorylation and transcriptional activity of STAT3, and STAT3 reactivation rescues the stem cell-like phenotype lost upon PIM3 knockdown.\",\n      \"method\": \"Pim-3 siRNA, CD24/ESA sorting for cancer stem cell subpopulations, STAT3 phosphorylation assay, STAT3 rescue experiment, tumorsphere and tumorigenicity assays\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — epistasis via STAT3 rescue; single lab; mechanism of STAT3 phosphorylation by PIM3 not directly demonstrated\",\n      \"pmids\": [\"28775772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The natural compound CSH-4044 (isolated from fermented wheat germ extract) inhibits PIM3 kinase activity in an ATP-competitive manner (co-crystal structure with PIM1 determined), and suppresses PIM3-driven BAD phosphorylation at Ser112 in pancreatic cancer cells.\",\n      \"method\": \"X-ray crystallography (PIM1 co-crystal structure), kinase profiling, phospho-BAD Western blot in pancreatic cancer cells\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus in-cell pharmacodynamic assay; preprint, not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PIM3 phosphorylates MAPK1 at T185 and Y187 in esophageal squamous cell carcinoma cells to promote proliferation and tumor development; corynoline directly binds PIM3, inhibits its kinase activity, and suppresses ESCC growth.\",\n      \"method\": \"Pull-down assay, cellular thermal shift assay, kinase assay, phosphorylation site identification, patient-derived xenograft tumor model\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple direct binding/kinase assays; novel substrate (MAPK1 at T185/Y187) identified; single lab\",\n      \"pmids\": [\"38128397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ETS1 transcription factor transcriptionally upregulates PIM3 in myocardial ischemia-reperfusion injury; hyperglycemia similarly drives nuclear translocation of YY1, which binds the PIM3 promoter and enhances PIM3 transcriptional activity, promoting cardiac hypertrophy.\",\n      \"method\": \"ChIP assay (YY1 binding to Pim3 promoter), luciferase reporter assay, ETS1/YY1 knockdown, mouse MIRI and diabetic models\",\n      \"journal\": \"Experimental cell research / Iranian journal of basic medical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and luciferase for transcriptional regulation; two independent studies (ETS1 and YY1) both using ChIP\",\n      \"pmids\": [\"40189183\", \"39850120\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PIM3 is a constitutively active serine/threonine kinase (CaMK group) that promotes cell survival primarily by phosphorylating BAD at Ser112 to inactivate its pro-apoptotic function; it also phosphorylates LANA (enabling KSHV reactivation), MLF2 at Ser65 (promoting metastasis via IRE1α/XBP1-S-MMP9), MAPK1 at T185/Y187, and CXCR4 at Ser339, while activating downstream signaling through STAT3, RhoA/GTPase, and Akt/mTOR/FoxO1 axes; PIM3 expression is transcriptionally driven by Ets-1, c-Myc, STAT3, and YY1, and post-translationally stabilized by TCTP through protection from ubiquitin-proteasomal degradation, while being suppressed by mTORC1-driven miR-33.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PIM3 is a constitutively active serine/threonine kinase of the CaMK group that functions as a pro-survival and pro-tumorigenic signaling node, integrating transcriptional inputs from ETS-family factors, c-Myc, STAT3, and YY1 with post-translational stabilization by TCTP to phosphorylate substrates that govern apoptosis, cell migration, stemness, and chromatin state [PMID:16818649, PMID:12748291, PMID:19154409, PMID:21646687, PMID:24165482, PMID:36150380]. Its best-characterized kinase activity is phosphorylation of the pro-apoptotic protein BAD at Ser112, which inactivates BAD and suppresses apoptosis across pancreatic, colon, and liver cancers; additional direct substrates include KSHV LANA (Ser205/206), MLF2 (Ser65), CXCR4 (Ser339), and MAPK1 (T185/Y187), linking PIM3 to viral reactivation, metastasis via the IRE1α/XBP1-S axis, chemokine receptor signaling, and MAPK pathway activation [PMID:16818649, PMID:19266083, PMID:41090348, PMID:36315303, PMID:38128397]. PIM3 also maintains endothelial barrier integrity by sustaining junctional VE-cadherin and catenin complexes, and in embryonic stem cells it suppresses the 2-cell-like totipotent state through an AMPK–HDAC4/5–H3K9ac chromatin axis [PMID:39627185, PMID:36150380]. Its expression is negatively regulated by mTORC1-driven miR-33a, which directly targets the PIM3 3′-UTR [PMID:29167471, PMID:25971209].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing that PIM3 is an oncogenic kinase: its identification as a transcriptional target of EWS/ETS fusions, combined with the finding that kinase-dead PIM3 suppresses transformation, demonstrated that PIM3 kinase activity is required for EWS/FLI1-driven tumorigenesis.\",\n      \"evidence\": \"Microarray, kinase-dead mutant (K69M) overexpression, NIH 3T3 soft agar and nude mouse tumorigenesis assays\",\n      \"pmids\": [\"12748291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation substrates unidentified at this stage\", \"Endogenous relevance beyond Ewing sarcoma unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defining PIM3 as an anti-apoptotic, pro-proliferative kinase: siRNA-mediated knockdown in hepatoma cells showed PIM3 is required for cell survival, establishing its role in epithelial cancer beyond Ewing sarcoma.\",\n      \"evidence\": \"RNA interference in human hepatoma cell lines with proliferation and apoptosis assays\",\n      \"pmids\": [\"15540201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular substrates mediating anti-apoptotic effect unknown\", \"In vivo relevance not yet tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying BAD Ser112 as the key pro-survival substrate: PIM3 directly phosphorylates BAD at Ser112 (not Ser136) to inactivate its pro-apoptotic function, providing the first defined substrate mechanism for PIM3-mediated survival signaling, replicated across pancreatic, colon, and liver cancer.\",\n      \"evidence\": \"shRNA knockdown, phospho-BAD Western blot, apoptosis assays in pancreatic and colon cancer cells; IHC co-localization in clinical tissues\",\n      \"pmids\": [\"16818649\", \"17270021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BAD is the sole survival substrate unclear\", \"Structural basis of PIM3-BAD interaction unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Positioning PIM3 downstream of STAT3 in stem cell biology: PIM3 was shown to be a STAT3-regulated gene in ES cells that promotes self-renewal and prevents apoptosis, expanding its role beyond cancer to developmental biology.\",\n      \"evidence\": \"Chimeric gp130 receptor, STAT3-ER inducible system, shRNA knockdown, clonal self-renewal assay in mouse ESCs\",\n      \"pmids\": [\"17717068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT3 binding to PIM3 promoter not shown by ChIP in this study\", \"Substrates mediating ES cell self-renewal undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defining transcriptional regulation of PIM3: Ets-1 was shown to directly bind the PIM3 promoter and drive constitutive expression, with c-Myc later shown to bind E-boxes within the Pim3 gene, establishing PIM3 as a convergence point of multiple oncogenic transcription factors.\",\n      \"evidence\": \"ChIP, luciferase reporter with promoter deletions, epistasis rescue (Ets-1 KD rescued by PIM3 cDNA); ChIP for c-Myc on Pim3 E-boxes in Burkitt lymphoma\",\n      \"pmids\": [\"19154409\", \"21646687\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of Ets-1 vs c-Myc vs STAT3 in different contexts not resolved\", \"Chromatin-level regulation of PIM3 promoter accessibility unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Expanding PIM3 substrates to viral latency and revealing non-cancer functions: PIM3 phosphorylates KSHV LANA at Ser205/206 to relieve transcriptional repression and enable lytic reactivation; separately, PIM3 localizes to lamellipodia in endothelial cells and is required for EC migration and tube formation.\",\n      \"evidence\": \"Co-IP, phosphorylation mapping, lytic gene transcription analysis for LANA; immunofluorescence co-localization with FAK, siRNA, Matrigel assay for ECs\",\n      \"pmids\": [\"19266083\", \"19229879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PIM3 kinase activity is directly required for lamellipodia localization unclear\", \"In vivo relevance of PIM3 in angiogenesis not yet demonstrated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating PIM3 as a tumor promoter in vivo and identifying a metabolic substrate: liver-specific PIM3 transgenic mice develop accelerated HCC only with carcinogen co-treatment, establishing PIM3 as a promoter not initiator; separately, PIM3 negatively regulates insulin secretion via SOCS6-mediated ERK1/2 inhibition in β-cells.\",\n      \"evidence\": \"Liver-selective transgenic mouse with DEN; Pim3-/- knockout mice with glucose tolerance testing, Co-IP of PIM3-SOCS6\",\n      \"pmids\": [\"20101231\", \"21099329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation of SOCS6 by PIM3 not demonstrated\", \"Mechanism by which PIM3 accelerates cell cycle in hepatocytes beyond BAD unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealing post-translational control of PIM3 stability: TCTP/TPT1 physically interacts with PIM3's C-terminus and protects it from ubiquitin-proteasome degradation, establishing that PIM3 protein levels are controlled at the post-translational level in addition to transcriptional regulation.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, domain mapping, proteasome inhibitor rescue, RNAi of TCTP\",\n      \"pmids\": [\"24165482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase responsible for PIM3 ubiquitination not identified\", \"Whether TCTP-PIM3 interaction is regulated by signaling unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying miR-33a as a negative regulator targeting PIM3 mRNA: miR-33a directly targets the PIM3 3′-UTR, and mTORC1 drives miR-33 expression via SREBP1/2, creating a feedback loop where mTORC1 activity suppresses PIM3.\",\n      \"evidence\": \"Dual luciferase reporter for 3′-UTR targeting; rapamycin treatment, TSC-null cells, in vivo mouse liver feeding model\",\n      \"pmids\": [\"25971209\", \"29167471\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional importance of mTORC1-miR-33-PIM3 axis in specific disease contexts not established\", \"Whether other miRNAs regulate PIM3 not explored systematically\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linking PIM3 to cancer stemness and STAT3-mediated EMT: PIM3 activates STAT3 phosphorylation to maintain pancreatic cancer stemness and promotes melanoma metastasis through STAT3-driven Slug/Snail/ZEB1 expression.\",\n      \"evidence\": \"siRNA with STAT3 rescue in pancreatic CSCs; shRNA with in vivo lung metastasis model in melanoma\",\n      \"pmids\": [\"28775772\", \"29370558\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PIM3 directly phosphorylates STAT3 or acts through an intermediary kinase not resolved\", \"Mechanism of PIM3 selectivity for stem-like subpopulations undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying RhoA and CXCR4 as PIM3-regulated effectors of cell migration: phosphoproteomics revealed PIM3 activates RhoA GTPase signaling for cytoskeletal rearrangement in liver cancer, and PIM3 phosphorylates CXCR4 at Ser339 to promote AML cell chemotaxis.\",\n      \"evidence\": \"Quantitative phosphoproteomics with RhoA activity assay; Co-IP of PIM3-pCXCR4 with migration assay\",\n      \"pmids\": [\"31994402\", \"32764981\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PIM3-RhoA phosphorylation event not identified\", \"CXCR4 Ser339 phosphorylation by PIM3 shown by single Co-IP without in vitro kinase assay confirmation\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealing a chromatin-regulatory role in totipotency suppression: PIM3 knockout in ESCs activates the MuERVL-marked 2-cell-like state through increased AMPK phosphorylation, nuclear export of HDAC4/5, and consequent H3K9 hyperacetylation on endogenous retroviral elements.\",\n      \"evidence\": \"Pim3 KO ESCs, AMPK phosphorylation analysis, HDAC4/5 localization, H3K9ac/me ChIP at MuERVL loci\",\n      \"pmids\": [\"36150380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PIM3 directly phosphorylates AMPK or suppresses its activation indirectly unknown\", \"Relevance of this axis in preimplantation embryos in vivo not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Validating CXCR4 as an in vivo metastatic effector downstream of PIM3: CRISPR knockout and overexpression combined with pharmacologic CXCR4 blockade (AMD3100) in hepatoblastoma demonstrated PIM3-CXCR4 epistasis in metastatic colonization.\",\n      \"evidence\": \"CRISPR/Cas9 KO and OE, tail-vein metastasis model, AMD3100 rescue, flow cytometry for surface CXCR4\",\n      \"pmids\": [\"36315303\", \"33864024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PIM3-CXCR4 axis operates in non-hepatoblastoma metastasis unknown\", \"Contribution of CXCR4 phosphorylation vs. surface trafficking not disentangled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Uncovering a tumor-suppressive context: endothelial PIM3 maintains VE-cadherin-based adherens junctions to preserve vascular barrier integrity, and PIM inhibition paradoxically increases metastatic colonization by disrupting the endothelial barrier.\",\n      \"evidence\": \"scRNA-seq of lung ECs, spontaneous metastasis models, PIM inhibitor treatment, junction protein analysis\",\n      \"pmids\": [\"39627185\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PIM3 substrate maintaining junctional stability not identified\", \"Whether this barrier-protective role counteracts tumor-cell-intrinsic PIM3 oncogenic effects in clinical settings unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying MLF2 Ser65 as a metastasis-promoting substrate and MAPK1 as a direct PIM3 substrate: PIM3 phosphorylates MLF2 at Ser65, stabilizing it via USP21 and activating the IRE1α/XBP1-S-MMP9 metastatic axis; separately, PIM3 phosphorylates MAPK1 at T185/Y187 to drive ESCC proliferation.\",\n      \"evidence\": \"CRISPR activation screen, Co-IP, phosphosite mapping, ubiquitination assay for MLF2; pull-down, CETSA, kinase assay for MAPK1 in PDX model\",\n      \"pmids\": [\"41090348\", \"38128397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MLF2 phosphorylation is PIM3-specific or shared with PIM1/PIM2 not tested\", \"Structural basis for PIM3 dual Ser/Thr and Tyr kinase activity on MAPK1 unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: the structural basis of PIM3 substrate selectivity, whether PIM3 directly phosphorylates STAT3 or AMPK, the identity of the E3 ligase that ubiquitinates PIM3, and how tumor-cell-intrinsic oncogenic activity is reconciled with endothelial barrier-protective functions in therapeutic targeting.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of PIM3 (only PIM1 co-crystal reported)\", \"E3 ubiquitin ligase for PIM3 not identified\", \"Context-dependent tumor-promoting vs. barrier-protective functions not reconciled mechanistically\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4, 12, 13, 19, 22, 28, 31]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [18, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 2, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 12, 15, 16, 23, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 11, 13, 21, 22, 31]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"BAD\",\n      \"SOCS6\",\n      \"TCTP\",\n      \"CXCR4\",\n      \"MLF2\",\n      \"MAPK1\",\n      \"STAT3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}